# DALY II Japan/MB-CART2019.1 for DLBCL

Source: https://onco.cc/trials/nct07288879/  
OnCo record `nct07288879` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Zamtocabtagene autoleucel in diffuse large b-cell lymphoma, run by Miltenyi Biomedicine GmbH, now recruiting.

## Summary

DALY II Japan/MB-CART2019.1 for DLBCL is a phase 2 interventional study registered as NCT07288879 by Miltenyi Biomedicine GmbH, with 31 participants planned, started 2025-12-11 and due to reach its primary completion in 2027-01-31. Interventions recorded: MB-CART2019.1. Conditions listed: DLBCL - Diffuse Large B Cell Lymphoma, CAR T Cell Therapy. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07288879
- Phase: 2
- Setting: A Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma.
- Sponsor: Miltenyi Biomedicine GmbH
- Enrolled: 31

## Sources

- ClinicalTrials.gov NCT07288879: https://clinicaltrials.gov/study/NCT07288879

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [Zamtocabtagene autoleucel](https://onco.cc/drugs/zamtocabtagene-autoleucel/)
- companies: [Miltenyi Biomedicine](https://onco.cc/companies/miltenyi-biomedicine/)

---
JSON: https://onco.cc/api/v1/entities/nct07288879.json